Merck & Cie v. Watson Labs., Inc.

E-Law Admin/ Mai 13, 2016/ Arzneimittelrecht Schweiz/ 0Kommentare

Merck & Cie v. Watson Labs., Inc., 2015-2063

In a case alleging infringement when defendant filed an Abbreviated New Drug Application (ANDA) seeking approval to manufacture and market generic versions of the patented Safyral and Beyaz oral contraceptive products, the District Court’s judgment holding that a claim of the patent is not invalid under the on-sale bar of 35 U.S.C. section 102(b) (2006), is reversed where because plaintiff’s offer to sell the patent was a premature commercial exploitation of its invention, the claim at issue is invalid under the on-sale bar.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2016/05/13



  • United States Federal Circuit


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar